Josh Bowerman Maps the Rapidly Changing World of Clinical Genomics

[This blog written by Chat GPT 5.6]

Josh Bowerman has developed a distinctive body of commentary on clinical genomics, particularly oncology diagnostics, liquid biopsy, early cancer detection, comprehensive genomic profiling, and minimal residual disease. His articles are brief, visually polished, and generally published on LinkedIn, but taken together they amount to something more substantial: an evolving map of how the precision-diagnostics industry is reorganizing itself.

Bowerman is not primarily reviewing individual scientific papers or comparing the analytical sensitivity of competing assays. His recurring questions are commercial and strategic:

Who is building what? Which parts of the cancer journey are companies trying to control? Are they developing capabilities internally or acquiring them? And, once the technology works, who can obtain reimbursement and achieve clinical adoption?

Bowerman writes from JBAndrews, an executive-search firm active in diagnostics and precision medicine. His LinkedIn profile, available here, reports approximately 29,000 followers. His position gives him an unusual source of market intelligence: conversations with companies about what expertise they are hiring, what capabilities they lack, and where they expect growth. In one discussion, he says explicitly that the firm’s view of deal activity often emerges from recruitment conversations.

These are therefore not neutral technology assessments or systematic evidence reviews. They are better understood as market cartography: concise narratives and graphics showing how a fragmented field may be consolidating.

From individual tests to the whole patient journey

The central idea running through Bowerman’s work is that oncology diagnostics can no longer be understood as a collection of isolated tests. The increasingly important competitive unit is the entire cancer journey.

His large “Cancer Diagnostics Landscape,” shown in the article available here, divides the market into four broad sectors:

Early detection and screening
Diagnosis and tumor profiling
Therapy selection and precision oncology
Monitoring, recurrence, and MRD

At the center are sequencing, data, and platform-enabling companies. Many diagnostic firms appear in more than one quadrant. Guardant, Caris, Tempus, Exact Sciences, Roche/Foundation Medicine, Datar, and others are no longer associated with only one clinical event. They are building portfolios extending across multiple stages of care.

This is Bowerman’s strongest and most useful contribution. Most readers in the field know separately that one company has an early-detection test, another has an MRD assay, and another has a tumor-profiling platform. His graphics make the strategic synthesis visible. Companies increasingly want to help identify a patient, characterize the cancer, guide treatment, and then continue testing through treatment response and recurrence surveillance.

That framework also makes the recent acquisition wave easier to understand. A company with genomic profiling but no MRD product has a conspicuous hole. A screening company may try to move downstream. An established laboratory can acquire an assay and development team rather than spend years building the capability internally.

MRD becomes a nearly mandatory capability

The most developed part of Bowerman’s series concerns minimal residual disease. One post begins bluntly: “Everyone wants an MRD platform.” The article is available here.

Bowerman inventories an increasingly crowded field: Foundation Medicine/Roche, CareDx, Natera, Guardant, Tempus/Personalis, Exact Sciences, NeoGenomics, Myriad, Labcorp, Quest, Adaptive Biotechnologies, Illumina, and ARUP. His accompanying Spider-Man meme shows Foundation Medicine, CareDx, and Tempus pointing at one another after each acquires or controls an MRD platform. The joke works because the strategic convergence is real: companies that once occupied distinguishable positions are assembling increasingly similar collections of capabilities.

Build or Buy?

Bowerman deepens the analysis in his “Build or Buy” article, available here. He places clonoSEQ, Signatera, Reveal, Plasma Detect, Precise MRD, Oncodetect, CLARISPECT, and Illumina’s anticipated kit on an organic-development timeline. He then traces acquisitions involving Inivata, Haystack Oncology, C2i Genomics, Foresight Diagnostics, SAGA Diagnostics, Naveris, and Personalis.

The accompanying Venn diagram distinguishes companies that largely developed an assay internally from those that acquired one. It also identifies hybrid cases. NeoGenomics acquired Inivata’s RaDaR technology, encountered patent litigation, and subsequently rebuilt the assay as RaDaR ST. Natera appears on both sides because it developed Signatera internally and later acquired Foresight, representing an additional external investment in MRD.

Bowerman’s graphic places the combined commitments for the displayed MRD acquisitions at approximately $3.74 billion. The exact total will inevitably change as new transactions occur, but the strategic signal is unmistakable: MRD has moved from being an interesting technology category to an asset that large diagnostics organizations increasingly believe they must possess.

The next contest will be commercial execution

Once nearly every major oncology-diagnostics company has an MRD offering, simply owning an assay is no longer a durable differentiator.

Bowerman therefore shifts the question from who has entered MRD to who can turn the science into reimbursement and adoption at scale.

That is an important transition. Genomics discussions often concentrate on sequencing depth, methylation, whole-genome methods, tumor-informed versus tumor-naïve designs, and increasingly small improvements in sensitivity. Those distinctions matter, but they do not automatically produce a successful clinical product.

The lively public discussions (reader comments eg here) surrounding several of Bowerman’s posts identify a second layer of competition:

Clinical evidence and guideline inclusion
Medicare and commercial coverage
Ordering and specimen logistics
Turnaround time
Report clarity
Electronic-record integration
Automation and laboratory efficiency
Commercial reach and physician confidence

Bowerman himself suggests that user experience will become increasingly important as differences among testing capabilities narrow. He notes that some companies are investing in ease of use, while others are outsourcing supporting infrastructure to specialized providers.

This may prove to be one of the most durable observations in the series. Every oncology sales representative can claim to offer the best test. A modest technical advantage may not persuade a physician to abandon a familiar workflow. A test that is easy to order, adequately reimbursed, clearly reported, and integrated into clinical practice may outperform a theoretically superior but operationally cumbersome competitor.

Early detection or recurrence detection?

Another Bowerman article poses a deceptively simple question: When we look back ten years from now, will early cancer detection or MRD have had the greater effect on cancer outcomes? The article and infographic are available here.

The graphic places the two opportunities at opposite points in the patient journey. Early detection attempts to identify cancer before clinical diagnosis. MRD attempts to identify residual or recurrent disease after diagnosis and treatment.

Bowerman reviews substantial activity on both sides. In early detection, he points to the NHS-Galleri debate and developments involving Guardant, Caris, ClearNote, Gene Solutions, Freenome, and DELFI. On the MRD side, he notes Illumina’s announced entry, Roche’s acquisition of SAGA, CareDx’s acquisition of Naveris, an FDA-approved MRD-guided therapy associated with Signatera, and continuing evidence generation by Personalis, Adaptive, NeoGenomics, Exact Sciences, Myriad, and others.

Bowerman does not attempt to settle the question, and probably should not. Its value lies in the comparison. Early detection addresses a vast population and the profound goal of finding cancer before symptoms, but faces demanding evidence standards and the challenge of managing downstream diagnostic workups. MRD begins with a known cancer population and often a clearer biological signal, but still must demonstrate that earlier molecular detection produces better treatment decisions and outcomes.

The juxtaposition helps explain why both fields attract extraordinary scientific and financial interest, while their clinical-development and reimbursement problems remain quite different.

Reimbursement as the reality test

Bowerman’s reimbursement article begins with the question that eventually confronts every diagnostic technology: “This is great, but how does it actually benefit patients?” The article is available here.

He organizes reported 2026 coverage expansions across screening and early detection, genomic profiling and therapy selection, treatment-response monitoring, and post-treatment MRD surveillance. He also makes a useful observation about transparency: Medicare, CMS, MolDX, and TRICARE coverage announcements were relatively easy to locate, while commercial-payer decisions were much harder to identify.

The graphic includes examples such as ColoSense and Shield in screening; ChromoSeq, TSO Comprehensive, and PanTracer LBx in profiling; NeXT Personal in treatment monitoring and surveillance; and TrueMRD in post-treatment monitoring.

Bowerman does not go deeply into the mechanics of coding, pricing, coverage criteria, testing frequency, or differences among payer policies. That is not his main subject. But he correctly recognizes reimbursement as the dividing line between an attractive scientific capability and a service that patients can actually receive.

Scientific validity creates the possibility of a clinical product. Coverage, payment, physician adoption, and workable operations determine whether that possibility becomes routine care.

Roche and the full oncology stack

Bowerman’s article on Roche, available here, applies his patient-journey framework to a single organization.

He assembles the pieces:

Freenome for blood-based early detection
Ventana and PathAI for pathology
Foundation Medicine for genomic profiling and companion diagnostics
Roche Pharma for therapy selection and therapeutics
SAGA Diagnostics for MRD and disease monitoring
SBX/Axelios for sequencing infrastructure
Roche Diagnostics for international distribution

Bowerman’s conclusion is that Roche increasingly resembles an end-to-end oncology infrastructure platform, rather than merely a diagnostics company making a series of acquisitions.

His Iron Man-style infographic may be playful, but it expresses a serious strategic concept. Roche possesses or influences technologies spanning screening, pathology, genomic characterization, drug selection, treatment, and longitudinal monitoring. It also has pharmaceutical assets, sequencing ambitions, regulatory experience, and global distribution.

Whether every component will ultimately function as a unified system is another question. But Bowerman is right to encourage readers to look at the collection as a whole rather than treating each transaction as an isolated news item.

Datar and an alternative path to scale

Bowerman’s Datar Cancer Genetics spotlight, available here, examines a company whose development differs from the familiar US venture-backed model.

He describes a portfolio spanning screening, diagnosis, comprehensive genomic profiling, therapy guidance, and MRD. Datar’s capabilities include tissue and liquid biopsy, circulating-tumor-cell analysis, and laboratory infrastructure in India, the United Kingdom, and Germany.

What interests Bowerman is not simply FDA clearance of CellDx-Tissue. He emphasizes what surrounds the cleared test: an international laboratory footprint, years of self-funded organic growth before a 2024 Series A, and early US traction despite the absence of a US laboratory.

The article should be read with the disclosure that Bowerman says JBAndrews has worked with Datar. It is therefore an informed company spotlight rather than independent clinical or investment diligence. Nevertheless, it supports his broader theme: the strategically important asset may be the organization and its longitudinal platform, not one individual assay.

Keeping an eye on the financial scoreboard

Bowerman also compares the revenue trajectories of leading oncology and precision-diagnostics companies in an animated post available here.

He excludes Exact Sciences from the moving comparison because its revenue—more than $3 billion in the period shown—would dominate the chart. He instead asks which emerging companies are gaining ground and whether recent scientific developments will change the rankings.

This financial perspective is a useful counterweight to conference enthusiasm. Scientific visibility, market capitalization, publication volume, and operating revenue are different measures. A company can be technologically exciting but commercially small. Another may appear less novel while possessing an established revenue engine, contracts, logistics, and payer relationships.

Bowerman’s revenue graphics ask readers to test the strategic narrative against actual commercial scale.

The larger message

Bowerman’s articles are most valuable when read as a connected series rather than as isolated LinkedIn posts. Together they advance several important propositions.

First, oncology diagnostics is reorganizing around longitudinal platforms. Screening, tumor profiling, therapy selection, and MRD are increasingly parts of one competitive map.

Second, MRD is becoming a nearly mandatory capability for major oncology-diagnostics companies. The question is no longer simply whether a company will enter the field, but whether it will build, buy, or partner—and whether it can convert the resulting assay into coverage and use.

Third, technical excellence alone may become less differentiating as the field matures. Evidence, reimbursement, workflow, user experience, and commercial execution will carry increasing weight.

Fourth, consolidation is not random. Many acquisitions fill identifiable gaps in the cancer continuum or add sequencing, pathology, data, and operational infrastructure beneath it.

Finally, promising science is not synonymous with a successful clinical product. Bowerman repeatedly returns to the practical questions of adoption, reimbursement, revenue, and organizational execution.

The limitations are clear. These are rapid strategic syntheses, not systematic reviews of clinical validity or utility. They do not independently adjudicate study quality, payer-policy details, comparative assay performance, or the wisdom of particular acquisition prices. The industry also changes so rapidly that any landscape graphic may need revision within months.

Bowerman appears comfortable with that provisional quality. He frequently invites readers to identify omitted companies or challenge his classifications, and the comments often improve the resulting map.

For newcomers trying to understand why clinical-genomics companies are launching, acquiring, partnering, and converging so rapidly, this is useful work. Individual facts may already be familiar to specialists. The value lies in assembling them into a coherent picture of where the industry is going.